News/ News/ Oncology ESMO: SpringWorks notches up a win in desmoid tumours Phil Taylor desmoid tumours, ESMO 2022, nirogacestat, Oncology, SpringWorks 0 Comment Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported Share X ESMO: SpringWorks notches up a win in desmoid tumours https://pharmaphorum.com/news/esmo-springworks-notches-up-a-win-in-desmoid-tumours/
News/ R&D SpringWorks spins out of Pfizer on rare disease mission Richard Staines Biotech, mental health, Pfizer, R&D, Rare diseases, SpringWorks 0 Comment A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks Share X SpringWorks spins out of Pfizer on rare disease mission https://pharmaphorum.com/transversal-categories/rd/springworks-spins-pfizer-rare-disease-rd-mission/
desmoid tumours, ESMO 2022, nirogacestat, Oncology, SpringWorks
0 Comment
